 |
|
Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
Abdullah Ozkaya, Zeynep Alkin, Mesut Togac, Sibel Ahmet, Irfan Perente, Muhittin Taskapili
Korean J Ophthalmol. 2017;31(5):424-430. Published online 2017 Sep 11 DOI: https://doi.org/10.3341/kjo.2016.0125
|
|
Citations to this article as recorded by
 Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression
Daniele Veritti, Valentina Sarao, Valentina Soppelsa, Carla Danese, Jay Chhablani, Paolo Lanzetta
Journal of Clinical Medicine.2022; 11(2): 325. CrossRef Long-Term Efficacy of a Treat-and-Extend Regimen with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: An Open-Label 12-Month Extension to the CANTREAT Study
Peter J. Kertes, Tom Sheidow, Geoff Williams, Mark Greve, Ivan J. Galic, Jason Baker
Ophthalmologica.2022; 245(3): 230. CrossRef Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review
Michel Giunta, Louis-Pierre Gauvin Meunier, Donald Nixon, Jeff Steeves, Jason Noble
Clinical Ophthalmology.2022; Volume 16: 2885. CrossRef Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
Vincent Daien, Robert P Finger, James S Talks, Paul Mitchell, Tien Y Wong, Taiji Sakamoto, Bora M Eldem, Jean-François Korobelnik
British Journal of Ophthalmology.2021; 105(11): 1475. CrossRef Fluorescein angiographic characteristic in predominantly classic and occult types of neovascular age-related macular degeneration treated with ranibizumab
Cemal Çavdarlı, Sebile Çomçalı, Pınar Topcu Yılmaz, Mehmet Numan Alp
Therapeutic Advances in Ophthalmology.2021; 13: 251584142110053. CrossRef Bimonthly, treat‐and‐extend and as‐needed ranibizumab in naïve neovascular age‐related macular degeneration patients: 12‐month outcomes of a randomized study
María Isabel López Gálvez, Lluís Arias Barquet, Marta. S. Figueroa, Alfredo García‐Layana, José M. Ruiz Moreno
Acta Ophthalmologica.2020;[Epub] CrossRef Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Federico Ricci, Francesco Bandello, Pierluigi Navarra, Giovanni Staurenghi, Michael Stumpp, Marco Zarbin
International Journal of Molecular Sciences.2020; 21(21): 8242. CrossRef Diagnosis and Treatment of Myopic Maculopathy
Asia-Pacific Journal of Ophthalmology.2019;[Epub] CrossRef FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA
Yuka Onishi, Tae Yokoi, Kaori Kasahara, Takeshi Yoshida, Natsuko Nagaoka, Kosei Shinohara, Yuichiro Kaneko, Mitsuki Suga, Kengo Uramoto, Akiko Ohno-Tanaka, Kyoko Ohno-Matsui
Retina.2019; 39(7): 1289. CrossRef Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis
Yongxian Su, Jiawei Wu, Yu Gu
Photodiagnosis and Photodynamic Therapy.2018; 22: 263. CrossRef
|